TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma

Modern Pathology

Volumn 22, Issue 11, 2009, Pages 1415-1422

  Albadine, Roula ^a   Latour, Mathieu ^a   Toubaji, Antoun ^a   Haffner, Michael ^a,b   Isaacs, William B ^b   A Platz, Elizabeth ^b,c   Meeker, Alan K ^a,b   Demarzo, Angelo M ^a,b   Epstein, Jonathan I ^a,b   Netto, George J ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Minute prostatic adenocarcinoma; TMPRSS2 ERG fusion

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; GENE; GENE DELETION; GENE FUSION; GENE LOCUS; HUMAN; HUMAN TISSUE; MALE; MINUTE PROSTATE ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; TISSUE MICROARRAY; TMPRSS2 GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALLELES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TRANS-ACTIVATORS;

EID: 70350686099     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.121     Document Type: Article

References (28)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648
2. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544
3. Wang J, Cai Y, Yu W, et al. Pleiotropic biological activities of alternatively spliced TMPRSS2-ERG fusion gene transcripts. Cancer Res 2008;68: 8516-8524
4. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826-832
5. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-888
6. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2-ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243
7. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007;20:467-473
8. Demichelis F, Fall K, Perner S, et al. TMPRSS2-ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26: 4596-4599.
9. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2-ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-45
10. Attard G, Clark J, Ambroisine L, et al., Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263
11. Cheville JC, Karnes RJ, Therneau TM, et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008;26:3930-3936
12. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406
13. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adeno-carcinomas. Mod Pathol 2009;22:359-365
14. Truskinovsky AM, Sanderson H, Epstein JI. Characterization of minute adenocarcinomas of prostate at radical prostatectomy. Urology 2004;64:733-737
15. Furusato B, Rosner IL, Osborn D, et al. Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? J Clin Pathol 2008;61:1038-1040
16. Harnden P, Naylor B, Shelley MD, et al. The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? A systematic review and meta-analysis. Cancer 2008;112:971-981 (Pubitemid 351304580)
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847
18. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007;20:921-928
19. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2-ERG fusions in prostate cancer indicates that genomic microdele-tion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-469
20. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14: 3380-3385
21. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75
22. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007;26:2667-2673
23. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005;216:34-63
24. Brown JA, Slezak JM, Lieber MM, et al. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clin Proc 1999;74:1214-1220
25. Lau WK, Blute ML, Bostwick DG, et al. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001;166:1692-1697
26. Attard G, Clark J, Ambroisine L, et al., Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263
27. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-3400
28. Toubaji A, Albadine R, Meeker AK, et al. Chromosome 21 copy number but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinoma: a large case-control radical prostatectomy cohort analysis. Mod Pathol 2009;22(suppl 1):189A